A phase II study of gefitinib plus S-1 after gefitinib monotherapy in patients with adenocarcinoma of the lung.

Trial Profile

A phase II study of gefitinib plus S-1 after gefitinib monotherapy in patients with adenocarcinoma of the lung.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 May 2016

At a glance

  • Drugs Gefitinib (Primary) ; Gimeracil/oteracil/tegafur
  • Indications Lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Apr 2016 Status changed from recruiting to active, no longer recruiting.
    • 30 Mar 2012 Planned End Date 1 Oct 2016 added as reported by University Hospital Medical Information Network - Japan record.
    • 30 Mar 2012 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top